
## **Beverley M Shields**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8993261/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Association of birthweight and penetrance of diabetes in individuals with HNF4A-MODY: a cohort study. Diabetologia, 2022, 65, 246-249.	6.3	2
2	Glycated haemoglobin measurements from UK Biobank are different to those in linked primary care records: implications for combining biochemistry data from research studies and routine clinical care. International Journal of Epidemiology, 2022, 51, 1022-1024.	1.9	7
3	Improvements in Awareness and Testing Have Led to a Threefold Increase Over 10 Years in the Identification of Monogenic Diabetes in the U.K Diabetes Care, 2022, 45, 642-649.	8.6	17
4	Continuous glucose monitoring demonstrates low risk of clinically significant hypoglycemia associated with sulphonylurea treatment in an African type 2 diabetes population: results from the OPTIMAL observational multicenter study. BMJ Open Diabetes Research and Care, 2022, 10, e002714.	2.8	2
5	Investigating the causal effect of maternal vitamin B12 and folate levels on offspring birthweight. International Journal of Epidemiology, 2021, 50, 179-189.	1.9	6
6	Latent Autoimmune Diabetes of Adults (LADA) Is Likely to Represent a Mixed Population of Autoimmune (Type 1) and Nonautoimmune (Type 2) Diabetes. Diabetes Care, 2021, 44, 1243-1251.	8.6	52
7	Choice of HbA1c threshold for identifying individuals at high risk of type 2 diabetes and implications for diabetes prevention programmes: a cohort study. BMC Medicine, 2021, 19, 184.	5.5	5
8	HbA1c performs well in monitoring glucose control even in populations with high prevalence of medical conditions that may alter its reliability: the OPTIMAL observational multicenter study. BMJ Open Diabetes Research and Care, 2021, 9, e002350.	2.8	5
9	Birth weight and diazoxide unresponsiveness strongly predict the likelihood of congenital hyperinsulinism due to a mutation in ABCC8 or KCNJ11. European Journal of Endocrinology, 2021, 185, 813-818.	3.7	2
10	Identifying routine clinical predictors of nonâ€adherence to secondâ€line therapies in type 2 diabetes: A retrospective cohort analysis in a large primary care database. Diabetes, Obesity and Metabolism, 2020, 22, 59-65.	4.4	10
11	Prior event rate ratio adjustment produced estimates consistent with randomized trial: a diabetes case study. Journal of Clinical Epidemiology, 2020, 122, 78-86.	5.0	10
12	Studies of insulin and proinsulin in pancreas and serum support the existence of aetiopathological endotypes of type 1 diabetes associated with age at diagnosis. Diabetologia, 2020, 63, 1258-1267.	6.3	98
13	Logistic regression has similar performance to optimised machine learning algorithms in a clinical setting: application to the discrimination between type 1 and type 2 diabetes in young adults. Diagnostic and Prognostic Research, 2020, 4, 6.	1.8	69
14	Histological validation of a type 1 diabetes clinical diagnostic model for classification of diabetes. Diabetic Medicine, 2020, 37, 2160-2168.	2.3	15
15	The challenge of diagnosing type 1 diabetes in older adults. Diabetic Medicine, 2020, 37, 1781-1782.	2.3	5
16	Strategies to identify individuals with monogenic diabetes: results of an economic evaluation. BMJ Open, 2020, 10, e034716.	1.9	8
17	Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Research and Care, 2020, 8, e001238.	2.8	43
18	TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea—a MASTERMIND study protocol. BMJ Open, 2020, 10, e042784.	1.9	17

#	Article	IF	CITATIONS
19	Association of Thyroid Function Test Abnormalities and Thyroid Autoimmunity With Preterm Birth. JAMA - Journal of the American Medical Association, 2019, 322, 632.	7.4	224
20	Clusters provide a better holistic view of type 2 diabetes than simple clinical features – Authors' reply. Lancet Diabetes and Endocrinology,the, 2019, 7, 669.	11.4	3
21	Disease progression and treatment response in data-driven subgroups of type 2 diabetes compared with models based on simple clinical features: an analysis using clinical trial data. Lancet Diabetes and Endocrinology,the, 2019, 7, 442-451.	11.4	280
22	Maternal and fetal genetic effects on birth weight and their relevance to cardio-metabolic risk factors. Nature Genetics, 2019, 51, 804-814.	21.4	402
23	Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010–2017. Diabetes, Obesity and Metabolism, 2019, 21, 1576-1584.	4.4	64
24	Persistent Câ€peptide is associated with reduced hypoglycaemia but not HbA <sub>1c</sub> in adults with longstanding Type 1 diabetes: evidence for lack of intensive treatment in UK clinical practice?. Diabetic Medicine, 2019, 36, 1092-1099.	2.3	32
25	Type 1 diabetes defined by severe insulin deficiency occurs after 30Âyears of age and is commonly treated as type 2 diabetes. Diabetologia, 2019, 62, 1167-1172.	6.3	100
26	What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study. BMC Medicine, 2019, 17, 79.	5.5	10
27	Patterns of postmeal insulin secretion in individuals with sulfonylurea-treated KCNJ11 neonatal diabetes show predominance of non-KATP-channel pathways. BMJ Open Diabetes Research and Care, 2019, 7, e000721.	2.8	9
28	Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18–50 years. BMJ Open, 2019, 9, e031586.	1.9	49
29	Zinc Transporter 8 Autoantibodies (ZnT8A) and a Type 1 Diabetes Genetic Risk Score Can Exclude Individuals With Type 1 Diabetes From Inappropriate Genetic Testing for Monogenic Diabetes. Diabetes Care, 2019, 42, e16-e17.	8.6	19
30	A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibody–Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy. Diabetes Care, 2019, 42, 208-214.	8.6	35
31	Fetal Genotype and Maternal Glucose Have Independent and Additive Effects on Birth Weight. Diabetes, 2018, 67, 1024-1029.	0.6	38
32	Genetic risk scores in adult-onset type 1 diabetes – Authors' reply. Lancet Diabetes and Endocrinology,the, 2018, 6, 169.	11.4	4
33	Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care, 2018, 41, 705-712.	8.6	67
34	Are we missing hypoglycaemia? Elderly patients with insulin-treated diabetes present to primary care frequently with non-specific symptoms associated with hypoglycaemia. Primary Care Diabetes, 2018, 12, 139-146.	1.8	24
35	Random non-fasting C-peptide testing can identify patients with insulin-treated type 2 diabetes at high risk of hypoglycaemia. Diabetologia, 2018, 61, 66-74.	6.3	30
36	Frequency and phenotype of type 1 diabetes in the first six decades of life: a cross-sectional, genetically stratified survival analysis from UK Biobank. Lancet Diabetes and Endocrinology,the, 2018, 6, 122-129.	11.4	291

#	Article	IF	CITATIONS
37	Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach. Clinical Epidemiology, 2018, Volume 10, 1869-1877.	3.0	14
38	A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin. Diabetologia, 2018, 61, 2520-2527.	6.3	65
39	Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care, 2018, 41, 1844-1853.	8.6	91
40	Effect of perchlorate and thiocyanate exposure on thyroid function of pregnant women from South-West England: a cohort study. Thyroid Research, 2018, 11, 9.	1.5	32
41	Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes, Obesity and Metabolism, 2018, 20, 2159-2168.	4.4	63
42	Exocrine pancreatic dysfunction is common in hepatocyte nuclear factor $1\hat{1}^2$ -associated renal disease and can be symptomatic. CKJ: Clinical Kidney Journal, 2018, 11, 453-458.	2.9	10
43	C-Peptide Decline in Type 1 Diabetes Has Two Phases: An Initial Exponential Fall and a Subsequent Stable Phase. Diabetes Care, 2018, 41, 1486-1492.	8.6	81
44	Towards a systematic nationwide screening strategy for MODY. Diabetologia, 2017, 60, 609-612.	6.3	12
45	Cohort profile for the MASTERMIND study: using the Clinical Practice Research Datalink (CPRD) to investigate stratification of response to treatment in patients with type 2 diabetes. BMJ Open, 2017, 7, e017989.	1.9	28
46	Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients. Diabetes Care, 2017, 40, 1017-1025.	8.6	111
47	lodine deficiency amongst pregnant women in South-West England. Clinical Endocrinology, 2017, 86, 451-455.	2.4	29
48	Adherence to Oral Glucose-Lowering Therapies and Associations With 1-Year HbA1c: A Retrospective Cohort Analysis in a Large Primary Care Database. Diabetes Care, 2016, 39, 258-263.	8.6	79
49	Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes. Diabetes Care, 2016, 39, 250-257.	8.6	132
50	Maternal thyroid function in pregnant women with a breech presentation in late gestation. Clinical Endocrinology, 2016, 85, 320-322.	2.4	2
51	Random nonâ€fasting C–peptide: bringing robust assessment of endogenous insulin secretion to the clinic. Diabetic Medicine, 2016, 33, 1554-1558.	2.3	50
52	South Asian individuals with diabetes who are referred for MODY testing in the UK have a lower mutation pick-up rate than white European people. Diabetologia, 2016, 59, 2262-2265.	6.3	28
53	Prematurity and Genetic Testing for Neonatal Diabetes. Pediatrics, 2016, 138, .	2.1	27
54	Practical Classification Guidelines for Diabetes in patients treated with insulin: a cross-sectional study of the accuracy of diabetes diagnosis. British Journal of General Practice, 2016, 66, e315-e322.	1.4	60

#	Article	IF	CITATIONS
55	Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes. Diabetes Care, 2016, 39, 1879-1888.	8.6	172
56	Maternal hypothyroxinaemia in pregnancy is associated with obesity and adverse maternal metabolic parameters. European Journal of Endocrinology, 2016, 174, 51-57.	3.7	58
57	A Type 1 Diabetes Genetic Risk Score Can Aid Discrimination Between Type 1 and Type 2 Diabetes in Young Adults. Diabetes Care, 2016, 39, 337-344.	8.6	231
58	Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?. PLoS ONE, 2016, 11, e0152428.	2.5	26
59	Can clinical features be used to differentiate type 1 from type 2 diabetes? A systematic review of the literature. BMJ Open, 2015, 5, e009088.	1.9	81
60	Most People With Long-Duration Type 1 Diabetes in a Large Population-Based Study Are Insulin Microsecretors. Diabetes Care, 2015, 38, 323-328.	8.6	104
61	Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation. Diabetes Care, 2015, 38, 1383-1392.	8.6	217
62	Lower Circulating B12 Is Associated with Higher Obesity and Insulin Resistance during Pregnancy in a Non-Diabetic White British Population. PLoS ONE, 2015, 10, e0135268.	2.5	74
63	Identification of Novel Genetic Loci Associated with Thyroid Peroxidase Antibodies and Clinical Thyroid Disease. PLoS Genetics, 2014, 10, e1004123.	3.5	150
64	Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia. Diabetologia, 2014, 57, 54-56.	6.3	164
65	The majority of patients with long-duration type 1 diabetes are insulin microsecretors and have functioning beta cells. Diabetologia, 2014, 57, 187-191.	6.3	240
66	Prevalence of Vascular Complications Among Patients With Glucokinase Mutations and Prolonged, Mild Hyperglycemia. JAMA - Journal of the American Medical Association, 2014, 311, 279.	7.4	257
67	Identifying Good Responders to Glucose Lowering Therapy in Type 2 Diabetes: Implications for Stratified Medicine. PLoS ONE, 2014, 9, e111235.	2.5	12
68	Lessons From the Mixed-Meal Tolerance Test. Diabetes Care, 2013, 36, 195-201.	8.6	61
69	Five-Year Follow-Up for Women With Subclinical Hypothyroidism in Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1941-E1945.	3.6	42
70	Response to Comment on: Besser et al. Lessons From the Mixed-Meal Tolerance Test: Use of 90-Minute and Fasting C-Peptide in Pediatric Diabetes. Diabetes Care 2013;36:195-201. Diabetes Care, 2013, 36, e222-e222.	8.6	0
71	Use of HbA1c in the Identification of Patients with Hyperglycaemia Caused by a Glucokinase Mutation: Observational Case Control Studies. PLoS ONE, 2013, 8, e65326.	2.5	101
72	Identifying clinical criteria to predict Type 1 diabetes, as defined by absolute insulin deficiency: a systematic review protocol. BMJ Open, 2012, 2, e002309.	1.9	3

#	Article	IF	CITATIONS
73	Home urine C-peptide creatinine ratio testing can identify type 2 and MODY in pediatric diabetes. Pediatric Diabetes, 2012, 14, n/a-n/a.	2.9	29
74	EDTA Improves Stability of Whole Blood C-Peptide and Insulin to Over 24 Hours at Room Temperature. PLoS ONE, 2012, 7, e42084.	2.5	39
75	The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia, 2012, 55, 1265-1272.	6.3	238
76	Urinary C-Peptide Creatinine Ratio Is a Practical Outpatient Tool for Identifying Hepatocyte Nuclear Factor 1-α/Hepatocyte Nuclear Factor 4-α Maturity-Onset Diabetes of the Young From Long-Duration Type 1 Diabetes. Diabetes Care, 2011, 34, 286-291.	8.6	123
77	Urine Câ€peptide creatinine ratio is an alternative to stimulated serum Câ€peptide measurement in lateâ€onset, insulinâ€treated diabetes. Diabetic Medicine, 2011, 28, 1034-1038.	2.3	32
78	Fetal Thyroid Hormone Level at Birth Is Associated with Fetal Growth. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E934-E938.	3.6	97
79	Urine C-Peptide Creatinine Ratio Is a Noninvasive Alternative to the Mixed-Meal Tolerance Test in Children and Adults With Type 1 Diabetes. Diabetes Care, 2011, 34, 607-609.	8.6	62
80	Maturity-onset diabetes of the young (MODY): how many cases are we missing?. Diabetologia, 2010, 53, 2504-2508.	6.3	560
81	Increased allâ€cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene. Diabetic Medicine, 2010, 27, 157-161.	2.3	96
82	Genetic influences on the association between fetal growth and susceptibility to type 2 diabetes. Journal of Developmental Origins of Health and Disease, 2010, 1, 96-105.	1.4	8
83	Stability and Reproducibility of a Single-Sample Urinary C-Peptide/Creatinine Ratio and Its Correlation with 24-h Urinary C-Peptide. Clinical Chemistry, 2009, 55, 2035-2039.	3.2	60
84	Phosphodiesterase 8B Gene Polymorphism Is Associated with Subclinical Hypothyroidism in Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4608-4612.	3.6	30
85	Cigarette Smoking during Pregnancy Is Associated with Alterations in Maternal and Fetal Thyroid Function. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 570-574.	3.6	64
86	Mutations in the Glucokinase Gene of the Fetus Result in Reduced Placental Weight. Diabetes Care, 2008, 31, 753-757.	8.6	30
87	Effective Treatment With Oral Sulfonylureas in Patients With Diabetes Due to Sulfonylurea Receptor 1 (SUR1) Mutations. Diabetes Care, 2008, 31, 204-209.	8.6	239
88	Measurement of Cord Insulin and Insulin-Related Peptides Suggests That Girls Are More Insulin Resistant Than Boys at Birth. Diabetes Care, 2007, 30, 2661-2666.	8.6	68
89	The Exeter Family Study of Childhood Health (EFSOCH): study protocol and methodology. Paediatric and Perinatal Epidemiology, 2006, 20, 172-179.	1.7	65
90	Paternal insulin resistance and its association with umbilical cord insulin concentrations. Diabetologia, 2006, 49, 2668-2674.	6.3	18

#	Article	IF	CITATIONS
91	Determinants of insulin concentrations in healthy 1-week-old babies in the community: Applications of a bloodspot assay. Early Human Development, 2006, 82, 143-148.	1.8	12
92	Assessing newborn body composition using principal components analysis: differences in the determinants of fat and skeletal size. BMC Pediatrics, 2006, 6, 24.	1.7	21
93	Evidence of genetic regulation of fetal longitudinal growth. Early Human Development, 2005, 81, 823-831.	1.8	75